Which company does Brigatinib belong to? Which generation of drug is it? Is it domestically produced or imported?

Brigatinib (also known as brigatinib), this popular drug in the field of lung cancer treatment, has been clinically proven to have good efficacy and safety. So, what is the research and development background and company ownership behind this drug? Which generation of drug is it? Is it domestic or imported?

First of all, brigatinib (AP26113) was originally developed by Ariad, but later Ariad was acquired by Takeda Pharmaceuticals, so now brigatinib has become an important product of Takeda Pharmaceuticals. This drug has demonstrated significant efficacy and advantages in the treatment of patients with ALK-positive non-small cell lung cancer (NSCLC).

So, which generation of drug does brigatinib belong to? It is a second-generation ALK tyrosine kinase inhibitor, mainly used to treat patients who are intolerant to or whose disease has progressed to first-generation ALK inhibitors (such as crizotinib). The development of this innovative drug provides more treatment options and hope for lung cancer patients.

Regarding the origin of brigatinib, it is not a domestically produced drug, but imported after strict approval. In March 2022, brigatinib was approved by the China National Medical Products Administration (NMPA) and officially entered the Chinese market. This drug effectively blocks the growth and spread of tumor cells by precisely inhibiting the ALK signaling pathway, thereby helping patients control their disease and improve their quality of life.

The launch of brigatinib undoubtedly brings a new dawn to patients with ALK-positive advanced non-small cell lung cancer. Clinical research data shows that it has obvious advantages in controlling brain metastases, improving survival benefits, and improving patients' quality of life. Especially for patients with brain metastases at baseline, the therapeutic effect of brigatinib is particularly significant. The intracranial lesion response rate and intracranial median disease duration of response are both better than those of the control group.

In terms of medication, brigatinib is available in three dosage specifications: 30 mg, 90 mg and 180 mg. The specific usage and dosage must be determined by the doctor according to the patient's specific conditions. Patients should pay close attention to their own conditions during use and report any discomfort or abnormal symptoms to their doctor in time.

It is worth mentioning that brigatinib has been included in the Category B list of medical insurance, which means that patients can enjoy preferential policies for medical insurance reimbursement during treatment, reducing the financial burden.

To sum up, brigatinib, as an innovative targeted drug from Takeda Pharmaceutical Company, not only enriches the treatment options for lung cancer in China, but also further promotes the development of precision treatment of lung cancer. Its emergence has brought new hope and treatment opportunities to patients with ALK-positive non-small cell lung cancer.